Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA. Nishio M, et al. Among authors: bordoni r. J Thorac Oncol. 2021 Apr;16(4):653-664. doi: 10.1016/j.jtho.2020.11.025. Epub 2020 Dec 14. J Thorac Oncol. 2021. PMID: 33333328 Free article. Clinical Trial.
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. von Pawel J, et al. Among authors: bordoni r. Eur J Cancer. 2019 Jan;107:124-132. doi: 10.1016/j.ejca.2018.11.020. Epub 2018 Dec 17. Eur J Cancer. 2019. PMID: 30562710 Clinical Trial.
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA. Forero-Torres A, et al. Among authors: bordoni re. Blood. 2015 Dec 24;126(26):2798-804. doi: 10.1182/blood-2015-06-644336. Epub 2015 Sep 16. Blood. 2015. PMID: 26377597 Free PMC article. Clinical Trial.
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.
Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki J, Elvin JA, Wollner M, Dvir A, -Gutman LS, Bordoni R, Peled N, Braiteh F, Raez L, Erlich R, Ou SH, Mohamed M, Ross JS, Stephens PJ, Ali SM, Miller VA. Schrock AB, et al. Among authors: bordoni r. Clin Cancer Res. 2016 Jul 1;22(13):3281-5. doi: 10.1158/1078-0432.CCR-15-1668. Epub 2016 Mar 1. Clin Cancer Res. 2016. PMID: 26933124
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ, Bordoni RE, Grant SC, Saleh MN, Reddy VB, Jerome ML, Dixon PM, Miley DK, Singh KP, Robert F. Allendorf DJ, et al. Cancer Chemother Pharmacol. 2015 Nov;76(5):949-55. doi: 10.1007/s00280-015-2869-6. Epub 2015 Sep 22. Cancer Chemother Pharmacol. 2015. PMID: 26395450 Clinical Trial.
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Zeidan AM, Cook RJ, Bordoni R, Berenson JR, Edenfield WJ, Mohan S, Zhou G, Asatiani E, Srinivas N, Savona MR. Zeidan AM, et al. Among authors: bordoni r. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):523-534. doi: 10.1016/j.clml.2022.01.012. Epub 2022 Jan 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35260349 Clinical Trial.
72 results